Researchers create a new way to overcome skin cancer for treatment

An international research team led by scientists at the University of Newcastle, the British University, has succeeded in disclosing biological mechanisms behind the failure of some patients to respond to a treatment known as “immune checkpoints”, which is one of the latest immunotherapy methods in solid crops, and they also have a new therapeutic formula. The study published in the journal “Nature Immunology” said that a kind of immune cell known as “funnel”, which is an important guard on the balance of the immune system responsible for the failure of this type of treatment. The researchers said that the braking of the PD-1 protein, which is one of the objectives of ICB treatments, in these cells specifically leads to an inverted result, as it promotes the growth of the crop instead of controlling it. The researchers conducted experiments on a genetic average definition model specifically designed to understand the resistance of immunotherapy, as well as analyzing samples of skin cancer patients. What is the ICB treatment? And immunotherapy that depends on the disruption of the so -called “checkpoints” in the immune system is a modern method aimed at motivating the body to fight cancer cells themselves. In the normal state, there are proteins on the surface of immune cells that act as brakes or controls. These cells prevent the attack of healthy tissues, and they are known as “checkpoints”. However, cancer cells use these brakes and use them as a cover to protect themselves from the attack of the immune system. Hence the idea of ​​treatment, as doctors give medications that disrupt these brakes, which free immune cells and give them the ability to attack the crop with more power, but this method, despite its success in some cases, does not succeed with all patients. It seems that this disruption can sometimes produce reverse results, especially if certain cells respond in an unexpected way within the immune system and allow the crop to grow instead of collapsing. For this reason, scientists are currently on their way to the development of new therapeutic methods that take these nuances into account, adding supportive medicines aimed at other types of protein within immune cells to increase the effectiveness of treatment and to avoid failure or aggravation of the disease. A revolution in the treatment of cancer and the latest immunotherapy with inspection indicates a revolution in the treatment of cancer for more than a decade, but its effectiveness was limited to a minority of patients, as more than 60% of cases did not respond to this type of treatment, despite its high costs and its large side effects. The researchers pointed out the ability to identify patients and give them effective treatment compositions that represent a performance of medical, strategic and economic importance. In the study, scientists found that the inhibition of immune control points stimulates the production of alternative immune proteins within organized T -cells, which increases the volatile properties of immunity and helps the crop to grow and evade the immune response. Among these proteins, the researchers focused on CD30 protein to discover that the target with a drug connection is already present in the treatment of blood cancer, which is ‘Bernotoxype vidoten’, which can restore the effectiveness of immune therapy even in resistance cases. The author who participated in the study said Shuba Amarath, head of the research team at Newcastle University, said that this discovery was not only limited to skin cancer, but also promises to patients with lung, colon, pancreatic and other solid tumors, which do not benefit from traditional immune treatments, adding that “with a simple addition to an anti -CD30- Treatment protocol can improve, and that we can improve the reaction. This stemy properties have shown, which can give them renewable ability to support cancer growth, even during treatment.